Gefitinib Gefticip 250 mg

Gefitinib is a medication primarily used in the treatment of non-small cell lung cancer (NSCLC) that harbors specific genetic mutations known as epidermal growth factor receptor (EGFR) mutations. It belongs to a class of drugs known as tyrosine kinase inhibitors, which work by blocking the activity of specific proteins involved in cancer cell growth and spread. Gefitinib is specifically indicated for patients with locally advanced or metastatic NSCLC whose tumors have EGFR mutations. It is typically taken orally in tablet form.